Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

NRG Therapeutics Announces $67million Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND
_↗ nrgtherapeutics.com
News Image

NRG Therapeutics, an innovative neuroscience company, has successfully closed a £50 million ($67 million) Series B financing round to advance its pipeline of treatments for neurodegenerative diseases. The financing was oversubscribed and led by SV Health Investors’ Dementia Discovery Fund, with new investors including British Business Bank, M Ventures, Novartis Venture Fund, and Criteria Bio Ventures joining existing investors Omega Funds and Brandon Capital. This substantial funding will enable NRG Therapeutics to generate clinical proof-of-concept data for its lead candidate, NRG5051, in patients with amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND). The company will also conduct a Phase 1b study to gather key clinical data in Parkinson's patients.

NRG5051 is a first-in-class, oral small molecule designed to inhibit the mitochondrial permeability transition pore (mPTP). The mPTP is a well-established driver of mitochondrial dysfunction and neuronal death, which are underlying pathologies in neurodegenerative diseases like ALS/MND and Parkinson's. Unlike other approaches, NRG's molecules inhibit pore opening through a novel mechanism of action. The company has demonstrated in preclinical models that NRG5051 is profoundly neuroprotective and significantly reduces neuroinflammation. Having completed IND-enabling studies, NRG5051 is on track to begin its first-in-human clinical studies in early 2026.

This financing provides a crucial runway to advance the lead program through clinical proof-of-concept studies and develop a portfolio of other small molecule candidates. The company believes its approach could be the first to offer disease-modifying treatment for sporadic ALS/MND and other neurodegenerative diseases. The need for new therapies is significant, as diseases like Parkinson's are the fastest-growing neurodegenerative conditions, and existing treatments only provide temporary symptomatic relief. The investment and the addition of new board members and a special advisor from Parkinson's UK highlight the strong confidence in NRG's approach and its potential to address the high unmet medical need for a growing number of people impacted by these devastating disorders.

Log In
Sign Up